Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of the NHS inhaler switchover policy on the UK inhaler industry.
We have made no specific assessment. We will continue to engage closely with industry and monitor the impact on businesses and supply chains.
The National Health Service remains committed to reducing the carbon impact of inhalers used in the treatment of respiratory conditions. All inhaler prescriptions, structured medication reviews or planned asthma reviews taking place in primary care should consider moving or facilitating patients to lower carbon options where it is clinically appropriate to do so.